Applied Materials Inc (NASDAQ:AMAT, XETRA:AP2) reported fiscal first quarter results that beat Wall Street expectations and issued strong guidance, sending its shares up more than 9% in after-hours trading on Thursday.
The semiconductor equipment maker posted revenue of $7.01 billion for the quarter ended January 25, down about 2% year-over-year but above the $6.89 billion consensus estimate.
BridgeBio Pharma (NASDAQ:BBIO) saw its shares rise more than 5% to about $77 on Thursday after reporting positive Phase 3 topline results for oral infigratinib in achondroplasia, with Jefferies analysts describing the data as “compelling.”
Achondroplasia is the most common form of dwarfism, a genetic condition that affects bone growth and results in short stature and disproportionate limb development.
Anheuser-Busch InBev (NYSE:BUD) reported mixed fourth quarter results on Thursday, with earnings topping analyst expectations but revenue coming in slightly below the consensus estimate amid ongoing volume declines.
For the fourth quarter, the world’s largest brewer posted underlying earnings of $0.95 per share, up 7.5% from a year earlier and above the $0.92 per share consensus estimate.
Crocs, Inc. (NASDAQ:CROX) shares rose nearly 20% following the company’s fourth quarter 2025 earnings report, as the footwear maker delivered results that exceeded Wall Street expectations.
The company reported adjusted earnings of $2.29 per share, beating the consensus estimate of $1.92 by about 19%.
Fastly Inc (NYSE:FSLY) shares surged nearly 64% on Thursday after the edge cloud company reported fourth quarter results and issued guidance that topped Wall Street expectations.
For the fourth quarter of 2025, Fastly reported adjusted earnings of $0.12 per share, beating the consensus estimate of $0.06.
HubSpot Inc (NYSE:HUBS) shares surged more than 9% on Thursday after the customer relationship management software company reported stronger-than-expected fourth-quarter results and approved a $1 billion share buyback program.
The company reported Q4 earnings per share of $3.09, exceeding analysts’ estimate of $2.99, while revenue rose 20% year-over-year to $846.7 million, surpassing the $830.8 million consensus.
AppLovin Corp (NASDAQ:APP) shares tumbled 16% in early trading Thursday, despite the mobile advertising software company reporting stronger-than-expected fourth-quarter earnings and raising its outlook for 2026.
The company posted revenue of $1.66 billion for Q4, up 66% from a year earlier and slightly above analyst estimates of $1.61 billion.
Sancus Lending Group Limited shares jumped 53% to 1.38p after the AIM-listed specialist property lender agreed to increase and extend its credit facility with Pollen Street Capital.
Sancus said it had entered into definitive legal agreements to expand the size of the facility from £200 million to £300 million and extend its maturity so that it will fall due no earlier than 11 February 2031.
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) shares opened 19.5% higher at 2.27p after the company reported positive preliminary interim results from its SLAB clinical trial in aged dogs.
The London-listed biotechnology group, which develops gene therapies for age-related diseases, said treated animals showed improved survival and functional outcomes during the dosing period.